The dormant form of TUBERCULOSIS where the person shows no obvious symptoms and no sign of the causative agent (Mycobacterium tuberculosis) in the SPUTUM despite being positive for tuberculosis infection skin test.
| Excerpt | Reference |
|---|
| "Low adherence to treatment of latent tuberculosis infection (TLTBI) diminishes TB prevention efforts." | ( Dorsinville, M; Li, J; Munsiff, SS; Tarantino, T, 2010) |
| "Treatment of latent tuberculosis infection reduces the risk of active TB in HIV positive individuals especially in those with a positive tuberculin skin test." | ( Adetifa, I; Akolo, C; Shepperd, S; Volmink, J, 2010) |
| "Treatment of latent tuberculosis infection (LTBI) generally includes isoniazid (INH), a drug that can cause serious hepatotoxicity." | ( Brooks-Wilson, A; Cook, VJ; Elwood, K; Fitzgerald, JM; Halaschek-Wiener, J; Marra, F; Richardson, K; Tang, M; Yamada, S, 2010) |
| "Randomised controlled trial of latent tuberculosis infection (LTBI) treatment in 10 clinics in Canada, Saudi Arabia and Brazil." | ( Al-Otaibi, B; Dion, MJ; Long, R; Menzies, D; Trajman, A; Zylberberg, D, 2010) |
| "Treatment for latent tuberculosis infection with isoniazid for 9 months (9INH) has poor completion and serious adverse events, while treatment for 4 months with daily rifampin (4RIF) has significantly higher completion and fewer adverse events." | ( Aspler, A; Dion, MJ; Khan, K; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2010) |
| "To evaluate a 10-year school-based latent tuberculosis infection (LTBI) screening program, targeting immigrant children in Montreal, Canada, and to identify predictive factors for refusal and, poor adherence to treatment." | ( Blais, D; Carle, ME; Lamarre, V; Minodier, P; Ovetchkine, P; Tapiero, B, 2010) |
| "Few studies have examined predictors of latent tuberculosis infection (LTBI) treatment completion in inner city populations in the United States." | ( Bethel, J; Colson, PW; El-Sadr, W; Franks, J; Hirsch-Moverman, Y, 2010) |
| "Guidelines recommend treatment of latent tuberculosis in patients at increased risk for active tuberculosis." | ( Bartlett, G; Menzies, D; Schwartzman, K; Smith, BM, 2011) |
| "The decision to treat latent tuberculosis infection in elderly patients should be made after careful consideration of risks and benefits." | ( Bartlett, G; Menzies, D; Schwartzman, K; Smith, BM, 2011) |
| "During screening for latent tuberculosis infection (LTBI), before anti-tumor-necrosis-factor-α treatment, most patients are already receiving immunosuppressive therapy." | ( Bélard, E; Brylov, A; Hetland, ML; Jensen, FK; Nordgaard-Lassen, I; Ravn, P; Ruhwald, M; Semb, S; Soborg, B; Thomsen, H; Werlinrud, AM, 2011) |
| "The indications for treatment for latent tuberculosis infection were revised in 2007 to reflect that any subject with a higher risk of tuberculosis regardless of age should be treated." | ( Nakazono, T; Shimao, T; Sugita, H; Tagawa, H; Takase, A; Takayanagi, K; Tezuka, N; Yamaguchi, T, 2011) |
| "who were treated for latent tuberculosis infection from August 2007 to December 2008 at our clinic." | ( Nakazono, T; Shimao, T; Sugita, H; Tagawa, H; Takase, A; Takayanagi, K; Tezuka, N; Yamaguchi, T, 2011) |
| "To assess the prevalence of latent tuberculosis infection (LTBI) in recently arrived refugees in the Northern Territory and to obtain comprehensive data for rates of treatment acceptance and completion for this condition." | ( Krause, VL; Trauer, JM, 2011) |
| "Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability." | ( Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE, 2011) |
| "To determine the incidence of latent tuberculosis infection and evaluate the follow-up protocol of the patients diagnosed with juvenile idiopathic arthritis (JIA) and other chronic rheumatologic diseases treated with anti-TNF-α treatment (etanercept, infliximab, adalimumab) in Turkey, 144 patients were evaluated retrospectively for the development of tuberculosis." | ( Akcakaya, N; Arisoy, N; Camcioglu, Y; Cokugras, H; Kasapcopur, O; Kilic, O, 2012) |
| "Although treatment for latent tuberculosis infection lowers the risk of reactivation of tuberculosis due to tumor necrosis factor alpha-blockers, it cannot completely inactivate tuberculosis." | ( Furuta, K; Ikeue, T; Morita, K; Nakagawa, A; Nishiyama, H; Sugita, T, 2011) |
| "Standard treatment for latent tuberculosis infection (LTBI) is 9 months daily isoniazid (9INH)." | ( Aspler, A; Esfahani, K; Menzies, D; Schwartzman, K, 2011) |
| "Contacts with latent tuberculosis infection (LTBI) are offered chemoprophylaxis to prevent active disease; however, the effectiveness of this intervention is unclear as treatment completion is generally low." | ( Ahuja, SD; Anger, HA; Harris, TG; Kreiswirth, BN; Li, J; Proops, D; Shashkina, E, 2012) |
| "The optimal treatment for latent tuberculosis infection consists of isoniazid (H, INH) for 9-12 months." | ( Arias, C; Clotet, L; Domínguez, A; Ferrer, A; Pina, JM; Sala, MR, 2012) |
| "This study evaluates completion of treatment for latent tuberculosis infection (LTBI) in Mexican immigrant children aged 1-18 years in a Community Health Center (CHC)." | ( Edick, T; Klee, D; O'Connor, ME; Young, J, 2012) |
| "The treatment of latent tuberculosis infection is well described in many national guidelines." | ( Fraisse, P, 2012) |
| "Notably, despite latent tuberculosis treatment, active tuberculosis was not prevented." | ( Fujio, K; Ishii, S; Nagafuchi, Y; Shoda, H; Sugiyama, H; Yamamoto, K, 2013) |
| "The cost was the sum of the cost of treating latent tuberculosis infection in all contacts plus the cost of treating tuberculosis in whom the disease was not avoided." | ( Clotet, L; Domínguez, A; Ferrer, A; Garrido, P; Pina, JM; Sala, MR; Salleras, L, 2013) |
| "Isoniazid treatment of latent tuberculosis infection (LTBI) is commonly prescribed in refugees and immigrants." | ( Biggs, BA; Butcher, K; Leder, K; Lemoh, C; Marshall, C; O'Brien, D, 2013) |
| "Treatment of latent tuberculosis (TB) infection is an important component of TB control programs in both high- and low-prevalence countries." | ( Parekh, MJ; Schluger, NW, 2013) |
| "Anti-TNF treatments may reactivate latent tuberculosis infection (LTBI); therefore, screening for LTBI is mandatory before starting any anti-TNF-α therapy." | ( Amicosante, M; Chimenti, MS; Chimenti, S; Chiricozzi, A; Saraceno, R; Sarmati, L; Specchio, F, 2014) |
| "The treatment of latent tuberculosis infection (LTBI) has been established as valid for patients at high risk for developing active tuberculosis." | ( , 2014) |
| "Treatment of latent tuberculosis infection (LTBI) is a key component in TB control strategies worldwide." | ( Bocchino, M; Matarese, A; Sanduzzi, A, 2014) |
| "Screening and therapy of latent tuberculosis infection (LTBI) is recommended in solid organ transplant (SOT)." | ( Humar, A; Kumar, D; Sidhu, A; Verma, G, 2014) |
| "The management of latent tuberculosis infection (LTBI) most commonly consists of a nine-month course of isoniazid (INH) therapy and is complicated by low adherence and completion rates." | ( Bartlett, M; Chang, H; Ellis, P; Friedland, G; Hung, A; Lukasiewicz, A; Peluso, MJ; Ramallo, J, 2014) |
| "Screening for latent tuberculosis infection (LTBI) is mandatory in patients with psoriasis prior to biological therapy." | ( Girolomoni, G; Gisondi, P; Lo Cascio, G; Pezzolo, E, 2014) |
| "This article examines costs to treat latent tuberculosis infection (LTBI) in an urban clinic population and highlights the potential effectiveness of an alternative transitional treatment regimen." | ( Fluegge, KR, 2014) |
| "Effective treatment of latent tuberculosis infection (LTBI) is an important component of TB elimination programs." | ( Abubakar, I; Harris, RJ; Lipman, MC; Muñoz, L; Stagg, HR; Zenner, D, 2014) |
| "Reactivation of latent tuberculosis infection (LTBI) is an important complication in patients treated with tumor necrosis factor-alpha (TNF-α) blocking agents." | ( Byeon, JS; Jo, KW; Jung, YJ; Kim, HC; Kim, KJ; Kim, YG; Lee, CK; Shim, TS; Yang, SK; Ye, BD; Yoo, B, 2014) |
| "Treatment of persons with latent tuberculosis (TB) infection at greatest risk of reactivation is an important component of TB control and elimination strategies." | ( Canizales, S; Carranza, C; Cruz-Hervert, P; Delgado-Sánchez, G; Ferreira-Guerrero, E; Ferreyra-Reyes, L; García-García, L; Guio, H; Molina, S; Mongua-Rodriguez, N; Montero-Campos, R; Ponce-de Leon, A; Sada, E; Sifuentes-Osornio, J; Téllez, N; Torres, M; Wilkinson, RJ; Young, DB, 2015) |
| "Treating latent tuberculosis infection is a strategy for eliminating tuberculosis, and isoniazid is recommended as preventive therapy." | ( Hamana, S; Matsuoka, S; Miyazawa, S; Moriyama, M; Nagai, S; Nakamura, H; Nirei, K, 2015) |
| "The screening and treatment of latent tuberculosis (TB) infection reduces the risk of progression to active disease and is currently recommended for HIV-infected patients." | ( Dirix, V; Domont, F; Goffard, JC; Hildebrand, M; Libin, M; Locht, C; Loyens, M; Martin, C; Mascart, F; Schepers, K; Van Vooren, JP; Wyndham-Thomas, C, 2015) |
| "Active and latent tuberculosis should be excluded and treated, if necessary, before giving ruxolitinib." | ( Bresser, P; Gerritsen, R; Janssen, J; Jauw, Y; Keizer, S; Koopman, B, 2015) |
| "The recommended treatment for latent tuberculosis (TB) infection in adults is a daily dose of isoniazid (INH) 300 mg for six months." | ( Barreira, D; Daher, A; Pinto, D; Pitta, L; Santos, T, 2015) |
| "To assess the prevalence of latent tuberculosis infection (LTBI) in patients with moderate to severe psoriasis receiving biologic therapy by using tuberculin skin test as a screening method and to evaluate the rate of conversion of tuberculin skin test (TST) during the treatment with biologics." | ( Dehesa, L; Kerdel, F; Medina-Gil, C; Vega, A, 2015) |
| "Prophylactic treatment of latent tuberculosis infection (LTBI) is necessary for controlling TB in low-incidence settings." | ( Bleything, S; Hunter, P; Lines, G, 2015) |
| "The preventive treatment of latent tuberculosis infection (LTBI) is of great importance for the elimination and control of tuberculosis (TB) worldwide, but existing screening methods for LTBI are still limited in predicting the onset of TB." | ( Ai, JW; Liu, QH; Ruan, QL; Zhang, WH, 2016) |
| "Targeted diagnosis and treatment of latent tuberculosis (TB) infection (LTBI) among persons with a high risk of exposure to TB or of developing TB when infected has been performed and monitored routinely in the Netherlands since 1993." | ( Cobelens, F; de Vries, G; Erkens, CG; Schimmel, H; Slump, E; van den Hof, S; Verhagen, M, 2016) |
| "Treatment of latent tuberculosis infection (LTBI) is essential for eradicating tuberculosis (TB)." | ( Huang, YW; Tsao, SM; Tsao, TC; Yang, SF; Yeh, YP, 2016) |
| "For treatment of latent tuberculosis infection (LTBI) overall, 49% of the respondents would refer management to infectious disease specialist or the health department, 37% would initiate isoniazid for 9 or 12 months, and 14% would use isoniazid for 6 months." | ( Carbone, L; Garcia-Rosell, M; Pattanaik, D; Raza, SH; Tran, NQ, 2017) |
| "The current recommendation for the treatment of latent tuberculosis infection (LTBI) in solid organ transplant candidates is isoniazid for 9 months, but this treatment has the main problem of frequently reaching the posttransplant period." | ( Guirao-Arrabal, E; Redel, J; Santos, F; Torre-Cisneros, J; Vaquero, JM, 2017) |
| "Psoriatic patients with latent tuberculosis infection (LTBI) need a prophylaxis before starting a treatment with biological drugs." | ( Conti, A; Galdo, G; Gisondi, P; Lasagni, C; Odorici, G; Pellacani, G; Piaserico, S, 2017) |
| "Treatment of latent tuberculosis infection (LTBI) is an important component of tuberculosis (TB) control, and this study updates a previous network meta-analysis of the best LTBI treatment options to inform public health action and programmatic management of LTBI." | ( Beer, N; Harris, RJ; Lipman, MC; Stagg, HR; van der Werf, MJ; Zenner, D, 2017) |
| "Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States." | ( Horsburgh, CR; Linas, BP; Marks, SM; Salomon, JA; Tasillo, A; Trikalinos, TA, 2017) |
| "Expanding latent tuberculosis treatment is important to decrease active disease globally." | ( Arevalo, B; Belknap, R; Borisov, AS; Caylà, JA; Chen, MP; Feng, PJ; Holland, D; Martinson, NA; Millet, JP; Miró, JM; Moro, RN; Scott, NA; Villarino, ME; Weiner, M; Wright, A, 2017) |
| "Persons with latent tuberculosis infection enrolled in South Africa would not routinely be treated programmatically." | ( Arevalo, B; Belknap, R; Borisov, AS; Caylà, JA; Chen, MP; Feng, PJ; Holland, D; Martinson, NA; Millet, JP; Miró, JM; Moro, RN; Scott, NA; Villarino, ME; Weiner, M; Wright, A, 2017) |
| "Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9-month course of isoniazid (9H)." | ( Biggs, B; Chen, C; Denholm, JT; Eisen, D; Leder, K; Matchett, E; McBryde, ES; Shultz, TR; Street, A, 2017) |
| "Children with latent tuberculosis and treated with isoniazid or isoniazid and rifampicin were included." | ( Bianchi, L; Chiappini, E; Cordola, C; de Martino, M; Galli, L; Montagnani, C; Piccini, P; Sollai, S; Tersigni, C; Venturini, E, 2018) |
| "Data from regular monitoring for latent tuberculosis infection [LTBI] during biologic treatment are lacking." | ( Chen, M; Hung, E; Ip, M; Lee, CK; Lui, G; Ng, SC; Tam, LS; Tang, W; Wong, SHV; Wu, JC, 2018) |
| "Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination." | ( Belknap, R; Chee, CBE; Reves, R; Zhang, Y, 2018) |
| "Treatment of latent tuberculosis infection (LTBI) is critical to the control and elimination of tuberculosis disease (TB) in the United States." | ( Allen, L; Bamrah Morris, S; Borisov, AS; Burton, D; Goldberg, S; LoBue, P; Njie, GJ; Vernon, A; Winston, CA; Yelk Woodruff, R, 2018) |
| "WHO recommends treatment for latent tuberculosis infection (LTBI) in the homeless and people who use drugs (PWUD)." | ( Coimbra Motta-Castro, AR; de Oliveira Landgraf de Castro, V; do Valle Leone de Oliveira, SM; Ferreira da Silva, E; Mello Miranda Paniago, A; Stábile, AC; Trajman, A, 2018) |
| "Treatment of latent tuberculosis (TB) infection (LTBI) effectively prevents its progression to active TB." | ( Chan, PC; Chang, LY; Chuang, YC; Huang, WC; Huang, YW; Ruan, SY; Sun, HY; Wang, JT; Wang, JY, 2018) |
| "Successful treatment of latent tuberculosis infection (LTBI) is essential to reduce tuberculosis (TB) incidence rates in low-burden countries." | ( Andersen, HE; Arnesen, TM; Dyrhol-Riise, AM; Madebo, T; Schein, YL; Tveiten, H; White, RA; Winje, BA, 2018) |
| "She was diagnosed as having and treated for latent tuberculosis infection and GU tract infection due to MAI." | ( Chinnakotla, S; Hassan, MA; Obeid, KM; Young, JH, 2018) |
| "Treatment of latent tuberculosis infection (LTBI) in high-risk groups is an effective strategy for TB control and elimination in low incidence settings." | ( Chapman, HJ; de Andrade Bezerra, JL; Hsu, H; Johnston, L; Lauzardo, M; Séraphin, MN; Yang, Y, 2019) |
| "There are insufficient data on the treatment of latent tuberculosis infection (LTBI) in elderly patients." | ( Baek, MS; Choi, H; Choi, JH; Hyun, IG; Kim, CH; Kim, HI; Kim, Y; Noh, CS, 2019) |
| "Among over 8000 patients treated for latent tuberculosis we found no evidence of acquired drug resistance, underscoring the safety of rifampin monotherapy for latent tuberculosis." | ( Aiona, K; Belknap, R; Flynn, AG; Haas, MK; Reves, R, 2020) |
| "An important problem limiting treatment of latent tuberculosis infection is the occurrence of adverse events with isoniazid." | ( Adjobimey, M; Benedetti, A; Campbell, JR; Cook, VJ; Eisenbeis, L; Fregonese, F; Johnston, JC; Menzies, D; Ruslami, R; Trajman, A; Valiquette, C, 2020) |
| "The treatment of latent tuberculosis infection (LTBI) in individuals at risk of reactivation is essential for tuberculosis control." | ( Carranza, C; de Oyarzabal, E; Ferreyra-Reyes, L; García-García, L; Herrera, MT; Juárez, E; Orozco, L; Ponce-de-León, A; Rangel-Escareño, C; Sada, E; Sifuentes-Osornio, J; Torres, M; Wilkinson, RJ, 2019) |
| "Treatment of latent tuberculosis infection (LTBI) plays a substantial role in the prevention of drug-susceptible tuberculosis (TB)." | ( Behr, MA; Benedetti, A; Britton, WJ; Dowdy, DW; Fox, GJ; Graham, SM; Marais, BJ; Marks, GB; Mason, P; Menzies, D; Nguyen, BH; Nguyen, CB; Nguyen, TA; Nguyen, VN; Tran, PT; Velen, K, 2020) |
| "Treatment data for latent tuberculosis infection (LTBI) among potential living kidney donors are scarce." | ( Abbo, LM; Anjan, S; Camargo, JF; Donato-Santana, C; Guerra, G; Morris, MI; Natori, Y; Simkins, J, 2020) |
| "Treatment of latent tuberculosis infection (LTBI) is an important strategy for active disease prevention." | ( Chen, SH; Hsu, HL; Huang, CC; Lee, CH; Liu, YJ; Putri, DU; Wang, I, 2020) |
| "All patients underwent screening for latent tuberculosis infection (LTBI) before starting tofacitinib, and patients with positive results were treated to prevent progression to active tuberculosis." | ( Hong, S; Kim, YG; Lee, CK; Nam, SH; Oh, JS; Shim, TS; Yoo, B, 2020) |
| "The detection and treatment of latent tuberculosis infection (LTBI) is a key step in eliminating tuberculosis (TB), but information on safety and on treatment interruption in elderly LTBI patients remains limited." | ( Chen, CY; Feng, JY; Huang, WC; Lee, SS; Li, CP; Lin, CB; Lin, SM; Pan, SW; Shu, CC; Su, WJ; Tung, CL; Wang, TY; Wei, YF, 2020) |
| "Four months of rifampin treatment for latent tuberculosis infection is safer, has superior treatment completion rates, and is as effective as 9 months of isoniazid." | ( Adjobimey, M; Al-Jahdali, H; Apriani, L; Baah, JO; Bastos, ML; Benedetti, A; Campbell, JR; Elwood, K; Hoeppner, V; Kim, HJ; Long, R; Menzies, D; Oxlade, O; Ruslami, R; Schwartzman, K; Toelle, BG; Trajman, A, 2020) |
| "Objective Treating latent tuberculosis infection (LTBI) is essential for eliminating the serious endemicity of tuberculosis." | ( Iwata, K; Miyakoshi, C; Morishita, N; Nishiwaki, M, 2020) |
| "Treatment of latent tuberculosis (LTBI) is important for tuberculosis (TB) prevention, and short course rifamycin-based therapies are preferred." | ( Aiona, K; Belknap, RW; Erlandson, KM; Haas, MK, 2021) |
| "Treatment of latent tuberculosis infection is recommended in patients receiving biologics." | ( Iba, A; Jo, T; Ono, S; Tomio, J; Yamana, H; Yasunaga, H, 2021) |
| "In patients starting biologics, treatment for latent tuberculosis infection was provided for different durations, including not only the recommended periods but also longer periods." | ( Iba, A; Jo, T; Ono, S; Tomio, J; Yamana, H; Yasunaga, H, 2021) |
| "Risk-targeted testing and treatment of latent tuberculosis infection (LTBI) is a critical component of the United States' (US) tuberculosis (TB) elimination strategy, but relatively low treatment completion rates remain a challenge." | ( Annan, E; Loethen, AD; Miller, TL; Stockbridge, EL, 2020) |
| "Treatment of latent tuberculosis infection (LTBI) decreases risk of progression to active tuberculosis." | ( Donahue, ML; Eberly, MD; Rajnik, M, 2021) |
| "Although latent tuberculosis infection (LTBI) treatment is given before anti-tumor necrosis factor (TNF) treatment, tuberculosis (TB) still develops in these patients and the risk factors are not well known." | ( Aksu, K; Kaptan, Y; Oksel, F; Sayiner, A; Suner, A; Taş, MN, 2021) |
| "Empiric treatment for latent tuberculosis infection (LTBI) was individually considered for immunocompromised patients." | ( Ang, S; Bagdasarian, N; Chan, HC; Chan, SM; Sinnathamby, A, 2021) |
| "Effective yet safe treatment of latent tuberculosis is important for preventing the spread of tuberculosis and the progression to active disease in pediatric patients." | ( Boyce, C; Huang, FS; Khalil, N; Kohlrieser, CM; Peck, GM; Schlaudecker, EP; Staat, MA, 2021) |
| "The prevalence of latent tuberculosis in this group, tolerance and therapeutic adherence in treated patients are described." | ( García-Tirado, J; Martin-Onraet, A; Osorio-López, EA; Vilar-Compte, D, 2021) |
| "Identification and treatment for latent tuberculosis infection (LTBI) are of great epidemiological importance of controlling tuberculosis (TB) worldwide." | ( Chou, CA; Dai, LH; Lee, CT; Liu, JW; Su, HA; Wu, CH; Yang, CC, 2021) |
| "Screening and treatment of latent tuberculosis infections (LTBI) are required before starting biologics in patients with immune-mediated inflammatory diseases (IMIDs)." | ( Chung, C; Jo, KW; Kim, YJ; Shim, TS, 2022) |
| "The mainstay therapy for latent tuberculosis infection is a 9-month regimen of daily isoniazid (9H) and a 3-month regimen of 12 once-weekly doses of isoniazid and rifapentine (3HP)." | ( Chang, TE; Huang, YH; Huang, YS; Perng, CL; Tseng, SY, 2021) |
| "Screening for and treatment of latent tuberculosis (TB) in patients with end-stage kidney disease (ESKD) are recommended." | ( Anibarro, L; Barcala, JM; De Souza-Galvao, ML; Gijon, P; Grijota, MD; Luque, R; Perez-Recio, S; Sanchez, F; Santin, M, 2022) |
| "Testing and treatment for latent tuberculosis infection (LTBI) can mitigate risk of active tuberculosis (TB) post-liver transplant (LT)." | ( Azar, MM; Cheung, H; Cohen, E; Foppiano Palacios, C; Malinis, M; Medvedeva, N, 2023) |
| "Testing and treatment for latent tuberculosis infection (LTBI) can mitigate risk of active tuberculosis (TB) post-liver transplant (LT)." | ( Azar, MM; Cheung, H; Cohen, E; Foppiano Palacios, C; Malinis, M; Medvedeva, N, 2023) |
| "The successful scale-up of a latent tuberculosis (TB) infection testing and treatment programme is essential to achieve TB elimination." | ( Abubakar, I; Bern, H; Booth, HL; Calvert, J; Clarke, AL; Crook, A; Duong, T; Francis, M; Ghanouni, A; Griffiths, C; Hack, V; Hamada, Y; Horne, R; Kunst, H; Layton, C; Lipman, M; Mandelbaum, M; Owen-Powell, E; Rangaka, MX; Sanders, K; Surey, J; White, PJ; Zenner, D, 2022) |
| "It is essential to strengthen the treatment of latent tuberculosis infection (LTBI) to break the chain of transmission." | ( Alves, BMCS; Araújo, WN; Borges, BJP; Campos, BA; Cola, JP; Jezus, SV; Noia Maciel, EL; Prado, TND; Sales, CMM; Tavares, NUL, 2023) |